The U.S. Food and Drug Administration recently issued warning letters to Neogen Corporation and Sciarra Aeromed, Inc., ...

In a pilot study, researchers evaluated the potassium-competitive acid blocker vonoprazan as a potential new treatment for ...

Primary back pain can stem from bone, joint, ligament, tendon, muscle, or any combination of these structures anywhere along the length of the horse’s body. As such, it’s a complicated condition to ...

The American Quarter Horse Foundation is accepting proposals for its annual Equine Research Grant Program, providing qualified researchers with an opportunity to advance scientific knowledge that can ...

Antimicrobial drugs (AMDs) have many benefits in equine medicine, but they can also have adverse effects of which practitioners should be aware. Antimicrobial drugs (AMDs) are important in equine ...

Research is shedding light on long-term outcomes for horses with PPID and how pergolide might affect TRH stimulation test results.

Velagliflozin shows promise as a safe and effective compound for treating insulin dysregulation and preventing laminitis by reducing the hyperinsulinemic response to dietary NSC. Laminitis developed ...

Equine recurrent uveitis (ERU) is often managed with topical corticosteroids to avoid unwanted consequences of systemic corticosteroids. A study evaluated penetration of two different steroid forms ...

Congenital and juvenile cataracts in horses are amenable to surgery due to the advent of foldable synthetic intraocular lenses. However, surgery doesn’t guarantee horses will achieve normal vision.

Leading equine supplement company delivers the most trusted, comprehensive health and wellness solutions tailored to the unique needs of each horse. SmartPak, the #1 Equine Health Brand, today ...

Foals must ingest colostrum or be provided with antibodies for immune protection. Colostrum, or the mare’s first milk, contains high levels of whole protein antibodies to protect the foal from disease ...

The Combating Illicit Xylazine Act reclassifying xylazine to a schedule three controlled substance is now in the Senate, and it’s unclear how this legislation might affect veterinarians’ access to the ...